Latest Market Diversification News

WA Kaolin Limited reports robust production growth and expanding sales, driven by new technical kaolin grades and strong forward orders for FY26.

Pacific Edge Limited reported a resilient FY25 performance despite losing Medicare coverage for its Cxbladder tests in the US, announcing a $20 million equity raise to support commercialization and growth.

RemSense Technologies reported a cash flow positive Q3 FY2025 with $420K net cash from operations and $1.403M in customer receipts, underpinned by renewed contracts and strategic partnerships across energy and industrial sectors.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.

Avenira Limited has ended its licensing agreement with Aleees, freeing the company to focus on a phased development of its Wonarah Phosphate Project aimed at early revenue generation in late 2025.

Ansell Limited delivered a robust FY25 half-year performance, marked by double-digit sales and earnings growth, successful KBU acquisition integration, and an upward revision of adjusted EPS guidance.

Alexium International Group reports a 16% sales increase in Q2 FY25 despite ongoing mattress market softness, driven by strategic product diversification and supply chain improvements.

Urbanise.com Limited reports a modest revenue increase in H1 FY2025 despite a Q2 license revenue dip, driven by customer churn and a contract dispute. The company achieves positive cash flow and advances banking partnerships to bolster its strata management platform.

Fenix Resources delivered a transformational December quarter, setting the stage to triple its iron ore production in 2025, backed by record shipments and a 177% increase in mineral resources at Iron Ridge.

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.